Topic: research and development
Boehringer Ingelheim has unveiled a €230 million ($268 million) investment in its biologics capacity.
GlaxoSmithKline’s former head of dermatology R&D, David Gordon, has joined Aclaris Therapeutics as its new chief medical officer.
German pharma company Bayer is said to be reviewing its R&D locations, with fears this may lead to the swinging of an ax across some operations.
Curis is bringing on board member Robert Martell, formerly CMO at Tesaro, as a full-time employee in the newly created role to head its R&D.
Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.
Takeda's plan involves signing on one or more large, long-term investors, as well as keeping its R&D pipeline alive by discarding programs that don't deliver.
We started the Rotten Tomatoes special feature last year to spotlight companies that haven't followed through on the tough ethical and scientific demands of the biotech industry. This year, we’re at it again with a bit of a twist: We included companies bruised in 2016 but revived in 2017.
Vir Biotech CEO Geroge Scangos has lined up infectious disease and immunology expert Skip Virgin from Washington University as its new R&D head.
AstraZeneca doubles down on Chinese business through a new drug development joint venture with a state-backed private equity firm.